Evidence map›Paper›PMID 32235371›Full record

ReviewInternational journal of molecular sciences2020

Curcumin and Colorectal Cancer: From Basic to Clinical Evidences.

Maria Pricci, Bruna Girardi, Floriana Giorgio, Giuseppe Losurdo, Enzo Ierardi, Alfredo Di Leo

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 3 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Novel cyclic CCancer cell international · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maria PricciTHD S. p.A., 42015 Correggio (RE), Italy.
Bruna GirardiTHD S. p.A., 42015 Correggio (RE), Italy.
Floriana GiorgioTHD S. p.A., 42015 Correggio (RE), Italy.
Giuseppe LosurdoGastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.ORCID 0000-0001-7038-3287
Enzo IerardiGastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.
Alfredo Di LeoGastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.
Piaggio (Italy) · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin diffuses through cell membranes into the endoplasmic reticulum, mitochondria, and nucleus, where it exerts actions, as an antioxidant property. Therefore, its use has been advocated for chemopreventive, antimetastatic, and anti-angiogenic purposes. We conducted a literature review to summarize studies investigating the relationship between curcumin and colorectal cancer (CRC). In vitro studies, performed on human colon cancer cell lines, showed that curcumin inhibited cellular growth through cycle arrest at the G2/M and G1 phases, as well as stimulated apoptosis by interacting with multiple molecular targets. In vivo studies have been performed in inflammatory and genetic CRC animal models with a chemopreventive effect. To improve curcumin bioavailability, it has been associated with small particles that increase its absorption when orally administered with excellent results on both inflammation and carcinogenesis. Curcumin has been used, moreover, as a component of dietetic formulations for CRC chemoprevention. These combinations showed in vitro and in vivo anticarcinogenetic properties in inflammation-related and genetic CRC. A synergic effect was suggested using an individual constituent dosage, which was lower than that experimentally used "in vivo" for single components. In conclusion, curcumin falls within the category of plant origin substances able to prevent CRC in animals. This property offers promising expectations in humans.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisCell CycleCell Line, TumorCell ProliferationClinical Studies as TopicColorectal NeoplasmsCurcuminDietary SupplementsDisease Models, AnimalDrug CompoundingDrug Evaluation, PreclinicalHumansTranslational Research, BiomedicalAntineoplastic Agents, PhytogenicCurcuminanimal modelapoptosiscell proliferationcellular culturecolorectal cancercurcumin

Identifiers

PMID32235371
PMCPMC7178200
OpenAlexW3013315866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.